WP
BMRN icon

WealthPLAN Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

WealthPLAN Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-270
Closed -$23.4K – 406
2023
Q2 		$23.4K Sell
270
-114
-30% -$10.7K ﹤0.01% 645
2023
Q1 		$37.3K Buy
+384
New +$39.8K ﹤0.01% 610

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

WealthPLAN Partners's BMRN Position: Q3 2023 in Review

WealthPLAN Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 270 shares — an estimated $23.4K sold.

WealthPLAN Partners first reported a position in BMRN in Q1 2023 and held it in 2 quarters. The position peaked at $37.3K in Q1 2023. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

  • WealthPLAN Partners reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • WealthPLAN Partners sold 270 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $23.4K.
  • WealthPLAN Partners first reported a position in BioMarin Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • WealthPLAN Partners's BioMarin Pharmaceuticals position peaked at $37.3K in Q1 2023.
  • 519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on WealthPLAN Partners's 13F filing for Q3 2023, filed 2 Nov 2023.